Furthermore, the sensitivity analysis that was performed after the exclusion of the CREDENCE data revealed a significant reduction in the risk of cardiovascular events compared with placebo in patients taking GLP-1 RAs with obesity (Table 3). Here, GLP1R is linked to obesity disorder.